JP Patent

JP2020536854A — 医学療法におけるセマグルチド

Assigned to Novo Nordisk AS · Expires 2020-12-17 · 5y expired

What this patent protects

本発明は、体重管理で使用するためのセマグルチドに関する。【選択図】なし

USPTO Abstract

本発明は、体重管理で使用するためのセマグルチドに関する。【選択図】なし

Drugs covered by this patent

Patent Metadata

Patent number: JP2020536854A
Jurisdiction: JP
Classification: —
Expires: 2020-12-17
Drug substance claim: No
Drug product claim: No
Assignee: Novo Nordisk AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.